Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LUGER, T. J.
Right arrow Articles by SCHIFFTHALER, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LUGER, T. J.
Right arrow Articles by SCHIFFTHALER, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1990, Vol. 64, No. 1 53-58
© 1990 The Board of Management and Trustees of the British Journal of Anaesthesia

research-article

ADDITIONAL SUBCUTANEOUS ADMINISTRATION OF FLUMAZENIL DOES NOT SHORTEN RECOVERY TIME AFTER MIDAZOLAM

T. J. LUGER, M.D., R. F. MORAWETZ, M.D. and G. MITTER SCHIFFTHALER, M.D.

Univ. Klinik für Anaesthesie und Allgemeine Intensivmedizin Anichstr. 35, A-6020 Innsbruck, Austria

Correspondence to T.J.L.

We assessed the efficacy of subcutaneous administration of flumazenil (Anexate, Roche), a specific benzodiazepine antagonist, in preventing resedation after initial reversal of midazolam sedation in 30 patients (ASA I—II) undergoing gynaecological surgery. In the post-operative period, the patients received flumazenil i.v. and placebo s.c. (group A), flumazenil i.v. and flumazenil s.c. (group B), or placebo i.v. and placebo s.c. (control group) in a randomized, double-blind procedure. Flumazenil (group A: 0.47 (SD 0.12) mg i.v., group B: 0.48 (0.06) mg i.v.) was significantly more effective than placebo in antagonizing the sedative effects of midazolam, but was accompanied by rebound sedation after 90 min. Additional s.c. administration of flumazenil 0.1 mg (group B) did not eliminate resedation. Undesirable side effects include nausea and vomiting. Local tolerance of the subcutaneous administration of flumazenil was good.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.